Skip to main content
Back
ETON logo

Eton Pharmaceuticals, Inc.

Data quality: 100%
Overbought
ETON
NASDAQ Healthcare Biotechnology
$23.81
▲ $1.49 (6.68%)
Mkt Cap: 638.53M
Day Range
$22.28 $23.90
52-Week Range
$11.09 $23.90
Volume
905,911
50D / 200D Avg
$16.72 / $16.77
Prev Close
$22.32

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -138.8 0.4
P/B 24.4 2.9
ROE % -18.2 3.7
Net Margin % -5.8 3.8
Rev Growth 5Y % 38.3 10.0
D/E 0.4 0.2

Key Takeaways

Revenue grew 38.33% annually over 5 years — strong growth
Debt/Equity of 0.35 — conservative balance sheet
Generating 10.19M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 66.61%
Capital efficient — spends only 0.42% of revenue on capex
ROIC of 0.15% — low return on invested capital

Growth

Revenue Growth (5Y)
38.33%
Revenue (1Y)104.94%
Earnings (1Y)N/A
FCF Growth (3Y)29.89%

Quality

Return on Equity
-18.19%
ROIC0.15%
Net Margin-5.75%
Op. Margin0.09%

Safety

Debt / Equity
0.35
Current Ratio1.57
Interest Coverage0.02

Valuation

P/E Ratio
-138.78
P/B Ratio24.41
EV/EBITDA8636.56
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 104.94% Revenue Growth (3Y) 58.96%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 38.33% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 79.95M Net Income (TTM) -4.60M
ROE -18.19% ROA -4.99%
Gross Margin 53.46% Operating Margin 0.09%
Net Margin -5.75% Free Cash Flow (TTM) 10.19M
ROIC 0.15% FCF Growth (3Y) 29.89%
Safety
Debt / Equity 0.35 Current Ratio 1.57
Interest Coverage 0.02 Dividend Yield 0.00%
Valuation
P/E Ratio -138.78 P/B Ratio 24.41
P/S Ratio 7.99 PEG Ratio -7.42
EV/EBITDA 8636.56 Dividend Yield 0.00%
Market Cap 638.53M Enterprise Value 621.83M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 79.95M 39.01M 31.64M 21.25M 21.83M
Net Income -4.60M -3.82M -936,000.0 -9.02M -1.96M
EPS (Diluted) -0.17 -0.15 -0.04 -0.36 -0.08
Gross Profit 42.74M 23.41M 21.06M 14.32M 19.21M
Operating Income 72,000.0 -2.60M -1.19M -8.26M -1.50M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 92.11M 76.12M 31.74M 25.03M 27.47M
Total Liabilities 65.96M 51.70M 16.26M 11.95M 9.84M
Shareholders' Equity 26.15M 24.43M 15.48M 13.08M 17.63M
Total Debt 9.25M 29.92M 5.40M 6.52M 6.70M
Cash & Equivalents 25.94M 14.94M 21.39M 16.31M 14.41M
Current Assets 60.58M 41.02M 26.84M 20.00M 23.60M
Current Liabilities 38.49M 19.95M 16.24M 6.46M 4.56M